Home › Neuroendocrine Carcinoma › Tennessee
Neuroendocrine Carcinoma clinical trials in Tennessee
4 studies for Neuroendocrine Carcinoma are looking for participants at sites in Tennessee.
Cities in Tennessee
A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs (SPECTRAL-1)
- Sarah Cannon Research Institute (SCRI), Nashville
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 25, 2026 · NCT07488923A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
- Erlanger Health, Inc, Chattanooga
- The West Clinic, Germantown
- SCRI Oncology Partners, Nashville
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 5, 2026 · NCT06330064A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer
- Sarah Cannon Research Institute - Oncology Partners, Nashville
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jul 9, 2026 · NCT07174583A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
- Baptist Memorial Hospital Baptist Cancer Center, Memphis
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated May 27, 2026 · NCT03093116From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.